Adamax
Summary
Adamax is an informal, vendor-market derivative of Semax, the ACTH(4-10)-based heptapeptide approved as a drug in Russia. It adds N-terminal acetylation and a C-terminal adamantane group, modifications intended to slow enzymatic degradation and improve brain penetration. No peer-reviewed study has tested Adamax in any model, so every claimed effect is an extrapolation from Semax pharmacology and general adamantane-peptide chemistry, not direct evidence.
Also known as: N-Acetyl Semax Adamantane, Adamantylated Semax, Adamax Peptide
Key Findings at a Glance
- • Adamax has no peer-reviewed literature: no PubMed-indexed study and no PubChem record exists for the compound, so its structure is defined only by vendor specifications.
- • The molecule is a Semax core with N-terminal acetylation and a C-terminal adamantane cage, two standard modifications aimed at protease resistance and blood-brain barrier penetration.
- • The adamantane-for-brain-penetration strategy has one published proof of concept in a different peptide class (the CNTF mimetic P21, FEBS Letters 2010), not in any Semax analog.
- • All benefit claims trace to parent Semax: BDNF upregulation in rat brain, serotonergic modulation, and Russian stroke studies, none of which tested the Adamax conjugate.
Adamax Overview & Molecular Profile
Adamax is a research-chemical modification of Semax, the synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered as a drug in Russia since 1994. As sold, Adamax combines two changes to the Semax scaffold: acetylation of the N-terminus and attachment of an adamantane cage at the C-terminus. Both are recognizable medicinal-chemistry moves: N-acetylation blocks aminopeptidase attack, and adamantane is a bulky lipophilic group used to raise membrane and blood-brain barrier permeability of peptides. A 2010 FEBS Letters study validated the adamantane strategy in a different neurotrophic peptide (the CNTF mimetic P21), where adamantane incorporation produced a brain-active compound after peripheral dosing in mice. No equivalent experiment has been published for Adamax. A PubMed search for the compound name returns no pharmacology, toxicology, or clinical literature, and it has no PubChem record, so its exact structure is defined only by vendor specifications. The closest evidence base is the parent molecule Semax, which has Russian clinical studies in stroke rehabilitation and a substantial preclinical record on BDNF upregulation and neurotransmitter modulation.
Mechanism of Action: Neuroprotection & Synaptic Plasticity
No mechanism has been measured for Adamax itself; the following is inferred from its components. The Semax core upregulates BDNF and NGF expression in hippocampus and cortex, modulates striatal serotonergic transmission, and potentiates amphetamine-evoked striatal dopamine release in rodent models while leaving baseline dopamine unchanged, without the steroidogenic activity of parent ACTH. The Pro-Gly-Pro tail of Semax already slows enkephalinase-mediated cleavage; N-terminal acetylation would additionally block aminopeptidase degradation. An adamantane cage raises lipophilicity and, in the CNTF-mimetic peptide P21, was shown to convert a peripherally unstable peptide into a brain-active one. Whether these modifications preserve, enhance, or abolish Semax-like activity in the Adamax conjugate has never been tested in a published study.
Adamax Pharmacokinetics: Designed Intent Without a Single Measurement
No absorption, distribution, metabolism, or elimination parameter has ever been published for Adamax. Everything that can be said about its pharmacokinetics is inference from the parent peptide and from one adamantane-peptide proof of concept in a different molecular class.
What the Parent Peptide Establishes
- • Unmodified Semax has a plasma half-life of roughly 2-3 minutes because of rapid cleavage by enkephalinase and carboxypeptidase, while its CNS effects outlast plasma clearance through sustained gene-expression changes (PMID: 14556513).
- • Semax research relies on intranasal delivery, which bypasses the blood-brain barrier via olfactory and trigeminal pathways; peak brain concentrations appear within 30 minutes in tracer studies. Adamax is sold for subcutaneous use, a route with no published CNS exposure data for this conjugate.
- • The Pro-Gly-Pro C-terminal extension of Semax partially protects against enkephalinase; Adamax replaces that free tail with an amidated adamantane group, which would be expected to further slow C-terminal cleavage, but this has not been measured.
The Adamantane Proof of Concept (Different Peptide)
- • Li et al. (FEBS Letters, 2010) showed that incorporating adamantane into a short CNTF-derived peptide produced a compound, P21, that improved learning and memory and promoted dentate gyrus neurogenesis after peripheral administration in mice, demonstrating that adamantane conjugation can yield brain-active peptides (PMID: 20600002).
- • That study measured behavioral and histological outcomes, not plasma or brain concentrations of the peptide, so even in the best case the pharmacokinetic parameters of adamantane conjugation remain unquantified.
- • Extrapolating from a CNTF-mimetic tetrapeptide core to an ACTH(4-10) heptapeptide core is a leap: conjugation can abolish activity as easily as enhance it, and no binding, gene-expression, or behavioral assay of Adamax exists to settle the question.
Research-Observed Effects
Cognitive Enhancement (Extrapolated From Semax)
Preliminary ResearchVendor materials claim Adamax improves focus, memory consolidation, and mental clarity. The only relevant evidence is indirect: parent compound Semax improved attention and memory measures in Russian clinical use and rodent models, and modulated striatal serotonin and amphetamine-evoked dopamine release in a 2005 neurochemistry study (PMID: 16362768). No published experiment has administered Adamax to any animal or human, so the claim cannot be rated beyond an extrapolation from the parent molecule.
Neurotrophic Upregulation (BDNF/NGF)
Preliminary ResearchThe Semax core of Adamax is documented to raise BDNF mRNA in rat hippocampus, frontal cortex, and basal forebrain within hours of administration, with effects persisting 24-48 hours (PMID: 14556513). Neurotrophic upregulation is the most plausible retained activity for the conjugate, but acetylation and adamantane attachment can change receptor and gene-expression profiles in either direction, and no Adamax measurement exists.
Neuroprotection in Ischemia Models
Preliminary ResearchSemax reduced infarct volume, normalized protein expression (CREB up, MMP-9 and c-Fos down), and improved outcomes in rat cerebral ischemia-reperfusion models (PMID: 34201112), and Russian clinicians have used it in acute stroke protocols. Whether an adamantane-conjugated Semax retains any of this activity is unknown; neuroprotection claims for Adamax specifically are unsupported by direct evidence.
Mood and Stress Modulation
Preliminary ResearchSemax shows anxiolytic and mild psychostimulant properties in animal and clinical observations, attributed to serotonergic modulation and enkephalinase inhibition. Adamax marketing repeats these claims and adds stress-resilience language. None of it has been tested for the conjugate; the claim rests entirely on the parent peptide's literature.
Safety & Tolerability
Adamax has never been studied in any published experiment: there is no direct safety, toxicity, or pharmacokinetic data for the compound in any species. The only adjacent evidence is the clinical record of unmodified Semax in Russia and preclinical work on an unrelated adamantane-peptide conjugate. From an evidence standpoint it is one of the least characterized nootropic peptides on the market.
Human data: No human or animal data exists for Adamax itself. Parent compound Semax has published human clinical studies in stroke rehabilitation, but those results cannot be assumed to transfer to an adamantane conjugate with unmeasured pharmacology.
Regulatory status: Not approved anywhere. Parent Semax is a registered drug in Russia and Ukraine; Adamax is an unregulated research chemical with no regulatory review.
-
A PubMed search for Adamax returns no pharmacology, toxicology, or clinical literature for the peptide, and the compound has no PubChem registry entry; its safety profile is wholly uncharacterized.
Theoretical - PubMed 29798983
In a Russian study of 110 ischemic stroke patients, unmodified Semax (10-day courses of 6000 mcg/day) raised plasma BDNF without a reported drug-related safety signal in that publication; this documents Semax tolerability, not Adamax.
Human trial - PubMed 20600002
Adamantane incorporation into a different neurotrophic peptide (the CNTF mimetic P21) produced a brain-active compound that was administered to mice without reported toxicity in that study; it supports the design strategy but establishes nothing about Adamax safety.
Animal
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published preclinical research protocols. Adamax is not approved by the US FDA for human use; regulatory status can differ in other countries, so see the regulatory status note in the safety section of this page. This information is provided for research reference only and does not constitute a dosing recommendation.
No published dosing data exists for Adamax in any species. Vendor communities discuss microgram-scale subcutaneous dosing extrapolated from Semax, but Semax itself is dosed intranasally in the clinical literature (200-600 mcg daily in Russian cognitive protocols), and the exposure profile of an adamantane conjugate given subcutaneously is uncharacterized. Any dosing figure for Adamax is anecdotal and cannot be referenced to primary research.
All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.
Research Studies & References
Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice
Li B, Wanka L, Blanchard J, et al.
FEBS Letters (2010)
This study is the scientific precedent for the design idea behind Adamax: attaching an adamantane cage to a short neurotrophic peptide. The authors synthesized Ac-DGGLAG-NH2 (P21), a CNTF-derived peptide carrying an adamantane-containing glycine mimetic, and showed that peripheral administration improved learning, short-term and spatial reference memory, and increased neurogenesis and maturation of newborn neurons in the dentate gyrus of adult mice. It demonstrates that adamantane conjugation can produce a brain-active peptide, though it says nothing about the Semax-derived Adamax molecule directly.
Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents
Eremin KO, Kudrin VS, et al.
Neurochemical Research (2005)
This neurochemical study characterized how the parent peptide Semax affects monoamine systems. Semax raised tissue and extracellular levels of the serotonin metabolite 5-HIAA in rat striatum over 1-4 hours, indicating activation of the serotonergic system, and strongly potentiated amphetamine-evoked dopamine release and locomotion without raising dopamine on its own. It anchors claims that Semax-family peptides modulate mood- and attention-related neurotransmission rather than acting as classical stimulants.
The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo
Dolotov OV, Seredenina TS, et al.
Doklady Biological Sciences (2003)
Using quantitative PCR across rat brain regions, this study showed that systemic Semax upregulates BDNF mRNA in the hippocampus, frontal cortex, and basal forebrain within hours, with expression changes persisting 24-48 hours. The regional pattern, concentrated in memory- and executive-function areas, established the neurotrophin hypothesis as central to Semax pharmacology. It is the core experiment behind BDNF claims made for Semax derivatives such as Adamax.
The efficacy of semax in the treatment of patients at different stages of ischemic stroke
Gusev EI, Martynov MY, et al.
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (2018)
In 110 ischemic stroke patients, Semax given as 10-day courses of 6000 mcg/day raised plasma BDNF levels regardless of whether rehabilitation started early or late, and higher BDNF correlated with better Barthel index outcomes and motor recovery. It is the largest published human study connecting Semax administration to a measurable neurotrophic biomarker, though it was not a placebo-controlled trial and documents the parent peptide, not Adamax.
Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion
Sudarkina OY, Filippenkov IB, et al.
International Journal of Molecular Sciences (2021)
In a transient middle cerebral artery occlusion model, Semax altered the post-ischemic brain protein landscape at 24 hours: active CREB rose in subcortical structures while MMP-9, c-Fos, and active JNK fell in cortical and subcortical tissue. The authors concluded that Semax suppresses inflammatory and cell-death programs while activating recovery mechanisms at both transcriptome and protein levels, providing the most detailed molecular map of Semax neuroprotection to date.
Frequently Asked Questions
Is Adamax the same as Semax?
No. Adamax is an unofficial derivative of Semax with two structural changes: an acetyl group on the N-terminus and an adamantane cage on the C-terminus. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a registered drug in Russia with published clinical studies. Adamax is sold only as a research chemical, and no peer-reviewed study has ever tested it, so the two compounds cannot be treated as interchangeable.
Has Adamax been studied in humans or animals?
No. A PubMed search for Adamax returns no pharmacology, toxicology, or clinical literature for the peptide, and it has no PubChem record. Every claim made for it is extrapolated from two bodies of work: the Semax literature (Russian clinical stroke studies plus rodent BDNF and neurochemistry experiments) and a 2010 FEBS Letters study showing that adamantane incorporation made a different neurotrophic peptide brain-active in mice.
What is the adamantane group supposed to do?
Adamantane is a rigid, highly lipophilic hydrocarbon cage. Medicinal chemists attach it to peptides to increase resistance to enzymatic degradation and to improve passage across lipid membranes including the blood-brain barrier. The strategy has one published peptide proof of concept (the CNTF mimetic P21), but conjugation effects are molecule-specific, and whether it helps or hurts Semax activity in the Adamax conjugate is unmeasured.
How does Adamax compare to N-Acetyl Semax Amidate?
Both are unofficial Semax derivatives sold as research chemicals. N-Acetyl Semax Amidate carries only the two end caps (N-acetyl and C-amide) and its structure is catalogued in PubChem (CID 172638603). Adamax adds the further adamantane modification and has no authoritative chemical registry entry. Neither compound has any published experimental study, so no evidence-based comparison of potency or duration is possible.
Is Adamax approved or regulated anywhere?
No. Adamax is not approved for human use in any country and is not on any regulator's review track. Its parent Semax is a registered prescription drug in Russia and Ukraine, but that registration covers only the unmodified peptide. Adamax is sold as a research chemical, and human use would be uncontrolled self-experimentation with an untested conjugate.
Related Peptides
View allSemax
Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH). It was developed in Russia as a nootropic and neuroprotective agent with applications in cognitive enhancement research.
N-Acetyl Semax Amidate
N-Acetyl Semax Amidate is a doubly end-capped derivative of Semax (Ac-MEHFPGP-NH2) catalogued in PubChem but never tested in a published study. What is known about it is inferred from Semax pharmacology.
P21
P21 (P021) is an adamantane-containing CNTF mimetic peptide that promotes dentate gyrus neurogenesis and showed disease-modifying effects in transgenic Alzheimer mouse models. No human trials have been published.
Dihexa
Dihexa is a synthetic peptide derivative of angiotensin IV that has been studied for potent nootropic and neuroprotective effects. It is reported to be extremely potent in promoting cognitive function.
Omberacetam
Omberacetam (Noopept, GVS-111) is a Russian-developed dipeptide mimetic of piracetam with nootropic and neuroprotective properties, studied in one comparative human trial and an extensive preclinical program.
Follow Peptpedia on Google
Add Peptpedia as a Preferred Source and Google can highlight our links with a "preferred" badge in your Top Stories and AI Overviews.